Form 4 for AKTX Akari Therapeutics Plc
Accepted 2024-12-26 00:00:00 ET · period of report 2024-12-23 · accession 0000950170-24-140431 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-26 | 2024-12-23 | AKTX | Neal James R | Dir | A - Grant | $0.00 | +2.00M | 24.22M | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares, par value $0.0001 per share | 2024-12-23 | A | A | 2,000,000 | $0.00 | 24,216,000 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. (F2) On December 23, 2024, the Reporting Person acquired 2,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. |